SEARCH

SEARCH BY CITATION

References

  • 1
    Haslam DW, James WP. Obesity. Lancet 2005;366:1197-1209.
  • 2
    Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 2010;6:71-82.
  • 3
    Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808.
  • 4
    Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-1788.
  • 5
    Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761.
  • 6
    Keaney JF, Jr., Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23:434-439.
  • 7
    Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286-289.
  • 8
    Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
  • 9
    Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol 2012;165:574-590.
  • 10
    Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008;159:1364-1367.
  • 11
    Sandhya N, Gokulakrishnan K, Ravikumar R, Mohan V, Balasubramanyam M. Association of hypoadiponectinemia with hypoglutathionemia in NAFLD subjects with and without type 2 diabetes. Dis Markers 2010;29:213-221.
  • 12
    Okauchi Y, Kishida K, Funahashi T, et al. Cross-sectional and longitudinal study of association between circulating thiobarbituric acid-reacting substance levels and clinicobiochemical parameters in 1,178 middle-aged Japanese men—The Amagasaki Visceral Fat Study. Nutr Metab (Lond) 2011;8:82.
  • 13
    Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006;70:1437-1442.
  • 14
    Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, Kohno N. A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism 2005;54:194-199.
  • 15
    Shin MJ, Lee JH, Jang Y, et al. Insulin resistance, adipokines, and oxidative stress in nondiabetic, hypercholesterolemic patients: leptin as an 8-epi-prostaglandin F2alpha determinant. Metabolism 2006;55:918-922.
  • 16
    Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol 2005;25:2368-2375.
  • 17
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
  • 18
    Jonsson AS, Flodin M, Hansson LO, Larsson A. Estimated glomerular filtration rate (eGFRCystC) from serum cystatin C shows strong agreement with iohexol clearance in patients with low GFR. Scand J Clin Lab Invest 2007;67:801-809.
  • 19
    Ahotupa M, Asankari TJ. Baseline diene conjugation in LDL lipids: an indicator of circulating oxidized LDL. Free Radic Biol Med 1999;27:1141-1150.
  • 20
    Annuk M, Fellstrom B, Akerblom O, Zilmer K, Vihalemm T, Zilmer M. Oxidative stress markers in pre-uremic patients. Clin Nephrol 2001;56:308-314.
  • 21
    Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005;51:1165-1176.
  • 22
    Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
  • 23
    Liao Y, Xuan W, Zhao J, et al. Antihypertrophic effects of adiponectin on cardiomyocytes are associated with the inhibition of heparin-binding epidermal growth factor signaling. Biochem Biophys Res Commun 2010;393:519-525.
  • 24
    Njajou OT, Kanaya AM, Holvoet P, et al. Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the health, aging and body composition study. Diabetes Metab Res Rev 2009;25:733-739.
  • 25
    Park SH, Kim JY, Lee JH, Park HY. Elevated oxidized low-density lipoprotein concentrations in postmenopausal women with the metabolic syndrome. Clin Chim Acta 2011;412:435-440.
  • 26
    Makedou K, Kourtis A, Gkiomisi A, et al. Oxidized low-density lipoprotein and adiponectin levels in pregnancy. Gynecol Endocrinol 2011;27:1070-1073.
  • 27
    Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4542-4548.
  • 28
    Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004;27:1680-1687.
  • 29
    Fargnoli JL, Sun Q, Olenczuk D, et al. Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2010;162:281-288.
  • 30
    Nomura S, Shouzu A, Omoto S, et al. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients. Blood Coagul Fibrinolysis 2009;20:440-447.
  • 31
    Tang H, Sebastian BM, Axhemi A, et al. Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol Clin Exp Res 2012;36:214-222.
  • 32
    Briggs DB, Giron RM, Malinowski PR, Nunez M, Tsao TS. Role of redox environment on the oligomerization of higher molecular weight adiponectin. BMC Biochem 2011;12:24.
  • 33
    Carazo A, Leon J, Casado J, et al. Hepatic expression of adiponectin receptors increases with non-alcoholic fatty liver disease progression in morbid obesity in correlation with glutathione peroxidase 1. Obes Surg 2011;21:492-500.
  • 34
    Plant S, Shand B, Elder P, Scott R. Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins. Diab Vasc Dis Res 2008;5:102-108.
  • 35
    Sliman SM, Patel RB, Cruff JP, et al. Adiponectin protects against hyperoxic lung injury and vascular leak. Cell Biochem Biophys, 2011. Electronic publication [DOI 10.1007/s12013-011-9330-1].
  • 36
    Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis 2012;220:587-592.
  • 37
    Kizer JR, Arnold AM, Benkeser D, et al. Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care 2012;35:415-423.